Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies

References

• Schwartz-Albiez R, Dörken B, Hofmann W, Moldenhauer G. The B cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein. J Immunol 1988; 140:905 - 14; PMID: 3257508
   PubMed Web of Science ®Google Scholar
• Link MP, Bindl J, Meeker TC, Carswell C, Doss CA, Warnke RA, et al. A unique antigen on mature B cells defined by a monoclonal antibody. J Immunol 1986; 137:3013 - 8; PMID: 3489782
   PubMed Web of Science ®Google Scholar
• Barrena S, Almeida J, Yunta M, López A, Fernández-Mosteirín N, Giralt M, et al. Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation. Leukemia 2005; 19:1376 - 83; http://dx.doi.org/10.1038/sj.leu.2403822; PMID: 15931266
   PubMed Web of Science ®Google Scholar
• Press OW, Eary JF, Badger CC, Martin PJ, Appelbaum FR, Levy R, et al. Treatment of refractory non-Hodgkin’s lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol 1989; 7:1027 - 38; PMID: 2666588
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Fig LM, Zasadny KR, Koral KF, DelRosario RB, Francis IR, et al. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol 1992; 10:1696 - 711; PMID: 1403053
   PubMed Web of Science ®Google Scholar
• Brown RS, Kaminski MS, Fisher SJ, Chang AE, Wahl RL. Intratumoral microdistribution of [131I]MB-1 in patients with B-cell lymphoma following radioimmunotherapy. Nucl Med Biol 1997; 24:657 - 63; http://dx.doi.org/10.1016/S0969-8051(97)00099-1; PMID: 9352537
   PubMed Web of Science ®Google Scholar
• Heider KH, Kiefer K, Zenz T, Volden M, Stilgenbauer S, Ostermann E, et al. A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies. Blood 2011; 118:4159 - 68; http://dx.doi.org/10.1182/blood-2011-04-351932; PMID: 21795744
   PubMed Web of Science ®Google Scholar
• Zhao X, Lapalombella R, Joshi T, Cheney C, Gowda A, Hayden-Ledbetter MS, et al. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood 2007; 110:2569 - 77; http://dx.doi.org/10.1182/blood-2006-12-062927; PMID: 17440052
   PubMed Web of Science ®Google Scholar
• Furman R, Andritsos L, Flinn IW, Forero-Torres A, Foon KA, Pagel JM, et al. Phase 1 Dose Escalation Study of TRU-016, An Anti-CD37 SMIPTM Protein In Relapsed and Refractory CLL. [ASH Annual Meeting Abstracts]. Blood2010; 116:56; https://ash.confex.com/ash/2010/webprogram/Paper32343.html.
   Google Scholar
• Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, et al. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. Cancer Res 2007; 67:8882 - 90; http://dx.doi.org/10.1158/0008-5472.CAN-07-0696; PMID: 17875730
   PubMed Web of Science ®Google Scholar
• Schuster M, Umana P, Ferrara C, Brünker P, Gerdes C, Waxenecker G, et al. Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering. Cancer Res 2005; 65:7934 - 41; PMID: 16140965
   PubMed Web of Science ®Google Scholar
• Weitzman J, Betancur M, Boissel L, Rabinowitz AP, Klein A, Klingemann H. Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia. Leuk Lymphoma 2009; 50:1361 - 8; http://dx.doi.org/10.1080/10428190903026500; PMID: 19562616
   PubMed Web of Science ®Google Scholar
• Iida S, Misaka H, Inoue M, Shibata M, Nakano R, Yamane-Ohnuki N, et al. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa. Clin Cancer Res 2006; 12:2879 - 87; http://dx.doi.org/10.1158/1078-0432.CCR-05-2619; PMID: 16675584
   PubMed Web of Science ®Google Scholar
• Iida S, Kuni-Kamochi R, Mori K, Misaka H, Inoue M, Okazaki A, et al. Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood. BMC Cancer 2009; 9:58; http://dx.doi.org/10.1186/1471-2407-9-58; PMID: 19226457
   PubMed Web of Science ®Google Scholar
• Saul R, Molyneux RJ, Elbein AD. Studies on the mechanism of castanospermine inhibition of alpha- and beta-glucosidases. Arch Biochem Biophys 1984; 230:668 - 75; http://dx.doi.org/10.1016/0003-9861(84)90448-X; PMID: 6424575
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99:754 - 8; http://dx.doi.org/10.1182/blood.V99.3.754; PMID: 11806974
   PubMed Web of Science ®Google Scholar
• Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21:3940 - 7; http://dx.doi.org/10.1200/JCO.2003.05.013; PMID: 12975461
   PubMed Web of Science ®Google Scholar
• Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003; 48:455 - 9; http://dx.doi.org/10.1002/art.10764; PMID: 12571855
   PubMed Web of Science ®Google Scholar
• Farag SS, Flinn IW, Modali R, Lehman TA, Young D, Byrd JC. Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood 2004; 103:1472 - 4; http://dx.doi.org/10.1182/blood-2003-07-2548; PMID: 14563637
   PubMed Web of Science ®Google Scholar
• Woyach JA, Lin TS, Lucas MS, Heerema N, Moran ME, Cheney C, et al. A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. Leukemia 2009; 23:912 - 8; http://dx.doi.org/10.1038/leu.2008.385; PMID: 19225537
   PubMed Web of Science ®Google Scholar
• Lapalombella R, Yeh YY, Wang L, Ramanunni A, Rafiq S, Jha S, et al. Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell 2012; 21:694 - 708; http://dx.doi.org/10.1016/j.ccr.2012.03.040; PMID: 22624718
   PubMed Web of Science ®Google Scholar
• Richards JO, Karki S, Lazar GA, Chen H, Dang W, Desjarlais JR. Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther 2008; 7:2517 - 27; http://dx.doi.org/10.1158/1535-7163.MCT-08-0201; PMID: 18723496
   PubMed Web of Science ®Google Scholar
• Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004; 199:1659 - 69; http://dx.doi.org/10.1084/jem.20040119; PMID: 15210744
   PubMed Web of Science ®Google Scholar
• Herbst R, Wang Y, Gallagher S, Mittereder N, Kuta E, Damschroder M, et al. B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther 2010; 335:213 - 22; http://dx.doi.org/10.1124/jpet.110.168062; PMID: 20605905
   PubMed Web of Science ®Google Scholar
• Tedder TF, Baras A, Xiu Y. Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Springer Semin Immunopathol 2006; 28:351 - 64; http://dx.doi.org/10.1007/s00281-006-0057-9; PMID: 17091246
   PubMed Web of Science ®Google Scholar
• Wang ZQ, Bapat AS, Rayanade RJ, Dagtas AS, Hoffmann MK. Interleukin-10 induces macrophage apoptosis and expression of CD16 (FcgammaRIII) whose engagement blocks the cell death programme and facilitates differentiation. Immunology 2001; 102:331 - 7; http://dx.doi.org/10.1046/j.1365-2567.2001.01171.x; PMID: 11298832
   PubMed Web of Science ®Google Scholar
• Ashraf SQ, Umana P, Mössner E, Ntouroupi T, Brünker P, Schmidt C, et al. Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis. Br J Cancer 2009; 101:1758 - 68; http://dx.doi.org/10.1038/sj.bjc.6605355; PMID: 19904275
   PubMed Web of Science ®Google Scholar
• Ziegler HW, Kay NE, Zarling JM. Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia. Int J Cancer 1981; 27:321 - 7; http://dx.doi.org/10.1002/ijc.2910270310; PMID: 6169660
   PubMed Web of Science ®Google Scholar
• Le Garff-Tavernier M, Decocq J, de Romeuf C, Parizot C, Dutertre CA, Chapiro E, et al. Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies. Leukemia 2011; 25:101 - 9; http://dx.doi.org/10.1038/leu.2010.240; PMID: 20975664
   PubMed Web of Science ®Google Scholar
• Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 2006; 103:4005 - 10; http://dx.doi.org/10.1073/pnas.0508123103; PMID: 16537476
   PubMed Web of Science ®Google Scholar
• Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001; 276:6591 - 604; http://dx.doi.org/10.1074/jbc.M009483200; PMID: 11096108
   PubMed Web of Science ®Google Scholar
• Desjarlais JR, Lazar GA. Modulation of antibody effector function. Exp Cell Res 2011; 317:1278 - 85; http://dx.doi.org/10.1016/j.yexcr.2011.03.018; PMID: 21459085
   PubMed Web of Science ®Google Scholar
• Lifely MR, Hale C, Boyce S, Keen MJ, Phillips J. Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. Glycobiology 1995; 5:813 - 22; http://dx.doi.org/10.1093/glycob/5.8.813; PMID: 8720080
   PubMed Web of Science ®Google Scholar
• Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, Kusunoki M, Iida S, Nakano R, et al. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng 2004; 87:614 - 22; http://dx.doi.org/10.1002/bit.20151; PMID: 15352059
   PubMed Web of Science ®Google Scholar
• Masuda K, Kubota T, Kaneko E, Iida S, Wakitani M, Kobayashi-Natsume Y, et al. Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity. Mol Immunol 2007; 44:3122 - 31; http://dx.doi.org/10.1016/j.molimm.2007.02.005; PMID: 17379311
   PubMed Web of Science ®Google Scholar
• Niwa R, Sakurada M, Kobayashi Y, Uehara A, Matsushima K, Ueda R, et al. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res 2005; 11:2327 - 36; http://dx.doi.org/10.1158/1078-0432.CCR-04-2263; PMID: 15788684
   PubMed Web of Science ®Google Scholar
• Thomas DA, O’Brien S, Kantarjian HM. Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia. [v.] Hematol Oncol Clin North Am 2009; 23:949 - 71, v; http://dx.doi.org/10.1016/j.hoc.2009.07.005; PMID: 19825447
   PubMed Web of Science ®Google Scholar
• Laporte JP, Isnard F, Garderet L, Fouillard L, Gorin NC. Remission of adult acute lymphocytic leukaemia with alemtuzumab. Leukemia 2004; 18:1557 - 8; http://dx.doi.org/10.1038/sj.leu.2403422; PMID: 15229619
   PubMed Web of Science ®Google Scholar
• Tibes R, Keating MJ, Ferrajoli A, Wierda W, Ravandi F, Garcia-Manero G, et al. Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer 2006; 106:2645 - 51; http://dx.doi.org/10.1002/cncr.21901; PMID: 16688777
   PubMed Web of Science ®Google Scholar
• Nijmeijer BA, van Schie ML, Halkes CJ, Griffioen M, Willemze R, Falkenburg JH. A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL. Blood 2010; 116:5930 - 40; http://dx.doi.org/10.1182/blood-2010-01-262006; PMID: 20844239
   PubMed Web of Science ®Google Scholar
• Piccaluga PP, Arpinati M, Candoni A, Laterza C, Paolini S, Gazzola A, et al. Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia. Leuk Lymphoma 2011; 52:325 - 7; http://dx.doi.org/10.3109/10428194.2010.529206; PMID: 21077738
   PubMed Web of Science ®Google Scholar
• Chevallier P, Robillard N, Houille G, Ayari S, Guillaume T, Delaunay J, et al. Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases. Leukemia 2009; 23:806 - 7; http://dx.doi.org/10.1038/leu.2008.303; PMID: 18971949
   PubMed Web of Science ®Google Scholar
• Keating M, Cheson B, Gribben JG, Robertson B, Nadler L. Innovative strategies for the treatment of CLL. Leuk Lymphoma 1996; 22:Suppl 2 53 - 64; http://dx.doi.org/10.3109/10428199609102703; PMID: 9021709
   PubMed Web of Science ®Google Scholar
• Johnson AJ, Lucas DM, Muthusamy N, Smith LL, Edwards RB, De Lay MD, et al. Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood 2006; 108:1334 - 8; http://dx.doi.org/10.1182/blood-2005-12-011213; PMID: 16670263
   PubMed Web of Science ®Google Scholar
• Rafiq S, Cheney C, Mo X, Jarjoura D, Muthusamy N, Byrd JC. XmAb-5574 antibody demonstrates superior antibody-dependent cellular cytotoxicity as compared with CD52- and CD20-targeted antibodies in adult acute lymphoblastic leukemia cells. Leukemia 2012; 26:1720 - 2; http://dx.doi.org/10.1038/leu.2012.40; PMID: 22333878
   PubMed Web of Science ®Google Scholar
• Pan X, Jarjoura D. Robust Estimation of the Variance of a Contrast in Linear Mixed Models. Joint Statistical Meetings 2009.
   Google Scholar
• Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979; 6:65 - 70
   Web of Science ®Google Scholar